Healthcare / BiotechnologyNasdaqGS
$18.32
-0.94 (-4.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-24.0M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$612M
P/E
N/A
•EV/EBITDA
N/A
•ROE
40.3%
↑Gross Margin
N/A
•Debt/Equity
-0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-39.9M · FCF $-33.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Net Income | $-39.9M | $-39.9M | $-29.2M | $-13.3M |
| EBITDA | $-40.8M | $-40.8M | $-26.8M | $-14.1M |
| EPS | -1.25 | -1.25 | -1.62 | -1.17 |
| Balance Sheet | ||||
| Debt/Equity | -0.02 | -0.02 | -0.06 | — |
| Current Ratio | 12.67 | 12.67 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-33.5M | $-33.5M | $-24.0M | $-12.5M |
| Returns | ||||
| ROE | 40.3% | 40.3% | 48.2% | 40.4% |
| Growth & Yield | ||||
| EPS Growth | 23.1% | 23.1% | -39.0% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.62 → -1.25
Residual
-30.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.